Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.82 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.73 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.73 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.73 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 2/20 | 0.58 |
| ▸ | NT5E | P21589 | 2/20 | 0.56 |
| ▸ | PNP | P00491 | 1/20 | 0.56 |
| ▸ | POLG | P54098 | 1/20 | 0.55 |
| ▸ | DTYMK | P23919 | 4/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.51 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18775385 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL157937 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL18785152 | 1.00 | POLB (0.82) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL16699229 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6TGM2 | |
| Deoxyguanosine Triphosphate SCHEMBL2820367 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6TGM2 | |
| Deoxyguanosine Triphosphate SCHEMBL252797 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6TGM2 | |
| SCHEMBL3042901 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6TGM2 | |
| Deoxyguanosine Triphosphate SCHEMBL12729493 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6TGM2 | |
| Deoxyguanosine Triphosphate SCHEMBL18785123 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6TGM2 | |
| Deoxyguanosine Triphosphate SCHEMBL80609 | 0.99 | POLB (0.81) | POLBP2RY2P2RY4P2RY6TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| US-20050136673-A1 | CMP slurry | XU WEN-QING (US) | 2005-06-23 | — | — | US | claimed |
| US-5480980-A | DNA SEQUENCES | BOEHRINGER MANNHEIM GMBH (DE) | 1996-01-02 | — | — | US | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240241107-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4333860-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | Board of Regents, The University of Texas System (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022236131-A1 | SERUM METABOLOMICS RELATED TO CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-11-10 | — | — | WO | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-9062392-B2 | Methods for isolating a peptide methods for identifying a peptide | INTEL CORPORATION (US) | 2015-06-23 | — | — | US | disclosed |
| US-9034659-B2 | Biosensors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150133305-A1 | METHODS FOR ISOLATING A PEPTIDE METHODS FOR IDENTIFYING A PEPTIDE | INTEL CORPORATION | 2015-05-14 | — | — | US | disclosed |
| WO-2013022545-A1 | HIGH SURFACE AREA FLEXIBLE CHEMIRESISTIVE BIOSENSOR BY OXIDATIVE CHEMICAL VAPOR DEPOSITION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110177964-A1 | CHEMOSENSORY ARRAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2011-07-21 | — | — | US | disclosed |
| US-20060252115-A1 | Synthesis and use of anti-reverse mRNA cap analogues | DARZYNKIEWICZ EDWARD | 2006-11-09 | — | — | US | disclosed |
| US-7074596-B2 | Synthesis and use of anti-reverse mRNA cap analogues | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050136673-A1 | CMP slurry | XU WEN-QING (US) | 2005-06-23 | — | — | US | disclosed |
| US-20050028450-A1 | CMP slurry | XU WEN-QING (US) | 2005-02-10 | — | — | US | disclosed |
| US-20030194759-A1 | Synthesis and use of anti-reverse mRBA cap analogues | DARZYNKIEWICZ, EDWARD (PL) | 2003-10-16 | — | — | US | disclosed |
| US-5087565-A | Synthetic process for preparation of 32 P-labeled nucleotides | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252115-A1 | Synthesis and use of anti-reverse mRNA cap analogues | RNGTT, RNMT, CPSF6 | POLB 228/4885P2RY2 2581/4885P2RY4 2153/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | POLB 3337/4885P2RY2 1037/4885P2RY4 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.